S100A9 Antibody - BSA Free

Western Blot: S100A9 Antibody [NB110-89726] - Cells were transfected with the pCMV6-ENTRY S100A9 cDNA or the pCMV6-ENTRY control for 48 hrs and lysed. Equivalent amounts of cell lysates (5 ug per lane) were separated by SDS-PAGE and immunoblotted with anti-S100A9.

Immunocytochemistry/Immunofluorescence: S100A9 Antibody [NB110-89726] - S100A9 antibody was tested in A431 cells with FITC (green). Nuclei and alpha-tubulin were counterstained with Dapi (blue) and Dylight 550 (red).

Immunohistochemistry-Paraffin: S100A9 Antibody [NB110-89726] - Key molecules of specific signaling pathways are assayed by immunohistochemistry in the colorectum of mice. Immunohistochemistry (200x magnification) of S100a9, in normal control, IgG Ab, and anti-S100a9 Ab-treated colorectal tissues of the colitis-associated cancer mouse (n = 4). Scale bar, 50 um. Staining scores were determined by semi-quantitative optical analysis. Image collected and cropped by CiteAb from the following publication (//journal.frontiersin.org/article/10.3389/fimmu.2017.01774/full), licensed under a CC-BY license.

Western Blot: S100A9 Antibody [NB110-89726] - Analysis of S100A9 Antibody in DMSO treated HL60 whole cell lysates.

Simple Western: S100A9 Antibody [NB110-89726] - Simple Western lane view shows a specific band for S100A9 in 0.5 mg/ml of Human PBMC's lysate. This experiment was performed under reducing conditions using the 12-230 kDa separation system.

Immunohistochemistry: S100A9 Antibody [NB110-89726] - Key molecules of specific signaling pathways are assayed by immunohistochemistry in the colorectum of mice. Immunohistochemistry (200× magnification) of (A) S100a9, (B) beta -catenin, (C) c-Myc, (D) p-Akt, (E) p-Smad2, & (F) Cxcl5 in normal control, IgG Ab, & anti-S100a9 Ab-treated colorectal tissues of the colitis-associated cancer mouse (n = 4). Scale bar, 50 µm. Staining scores were determined by semi-quantitative optical analysis. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/29326691), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Immunohistochemistry: S100A9 Antibody [NB110-89726] - Key molecules of specific signaling pathways are assayed by immunohistochemistry in the colorectum of mice. Immunohistochemistry (200× magnification) of (A) S100a9, (B) beta -catenin, (C) c-Myc, (D) p-Akt, (E) p-Smad2, & (F) Cxcl5 in normal control, IgG Ab, & anti-S100a9 Ab-treated colorectal tissues of the colitis-associated cancer mouse (n = 4). Scale bar, 50 µm. Staining scores were determined by semi-quantitative optical analysis. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/29326691), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Immunohistochemistry: S100A9 Antibody [NB110-89726] - Key molecules of specific signaling pathways are assayed by immunohistochemistry in the colorectum of mice. Immunohistochemistry (200× magnification) of (A) S100a9, (B) beta -catenin, (C) c-Myc, (D) p-Akt, (E) p-Smad2, & (F) Cxcl5 in normal control, IgG Ab, & anti-S100a9 Ab-treated colorectal tissues of the colitis-associated cancer mouse (n = 4). Scale bar, 50 µm. Staining scores were determined by semi-quantitative optical analysis. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/29326691), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Immunohistochemistry: S100A9 Antibody [NB110-89726] - Key molecules of specific signaling pathways are assayed by immunohistochemistry in the colorectum of mice. Immunohistochemistry (200× magnification) of (A) S100a9, (B) beta -catenin, (C) c-Myc, (D) p-Akt, (E) p-Smad2, & (F) Cxcl5 in normal control, IgG Ab, & anti-S100a9 Ab-treated colorectal tissues of the colitis-associated cancer mouse (n = 4). Scale bar, 50 µm. Staining scores were determined by semi-quantitative optical analysis. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/29326691), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Immunohistochemistry: S100A9 Antibody [NB110-89726] - Key molecules of specific signaling pathways are assayed by immunohistochemistry in the colorectum of mice. Immunohistochemistry (200× magnification) of (A) S100a9, (B) beta -catenin, (C) c-Myc, (D) p-Akt, (E) p-Smad2, & (F) Cxcl5 in normal control, IgG Ab, & anti-S100a9 Ab-treated colorectal tissues of the colitis-associated cancer mouse (n = 4). Scale bar, 50 µm. Staining scores were determined by semi-quantitative optical analysis. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/29326691), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Immunohistochemistry: S100A9 Antibody [NB110-89726] - Effects of anti-S100a9 Ab administration on the azoxymethane (AOM)/dextran sulfate sodium (DSS)-induced colitis-associated cancer development. (A) Experimental procedure of the control group & the AOM/DSS group treated with IgG Ab or anti-S100a9 Ab. (B) DAI of the IgG Ab or anti-S100a9 Ab-treated AOM/DSS mice & normal controls. (C) General observation of the colorectums in mice at the end of the 13th & 18th week. (D) Colon length, tumor rate, & number of macroscopic neoplasms were statisticed at 13 & 18 weeks, individually. n = 5–9 per group. Results were representative of the three experiments performed. (E) Histopathological examination of colon sections was shown under the Pannoramic Viewer (H&E staining, upper panels: original magnification 10×, scale bar: 2000 µm; lower panels: original magnification 200×, scale bar: 100 µm). Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/29326691), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Immunohistochemistry: S100A9 Antibody [NB110-89726] - Effects of anti-S100a9 Ab on the frequency of neutrophils, macrophages, & dendritic cells (DCs) in the colon of the dextran sulfate sodium (DSS) mouse model. (A) Colon lamina propria cells were isolated from normal control & IgG Ab or anti-S100a9 Ab-treated DSS mice at day 6 post-DSS colitis induction. Frequencies of neutrophils, macrophages, & DCs in the colon were determined by flow cytometry. Cells were gated on CD45+CD3−CD4−CD11b+Ly6G+, CD45+CD3−CD4−CD11b+F4/80+, & CD45+CD3−CD4−CD11b+CD11c+ populations respectively. Representative flow cytometric figures were shown. The percentage of cells was presented as the mean ± SEM of four to six individual mice per group. *p < 0.05 in a one-way analysis of variance followed by Bonferroni correction. Data were representative of three independent experiments. (B) Immunohistochemical staining of myeloperoxidase (MPO), CD68, & CD11c proteins in the normal control & IgG Ab or anti-S100a9 Ab-treated colitis mice at day 6 (left panels: original magnification 40×, scale bar: 200 µm; right panels: original magnification 200×, scale bar: 50 µm). Staining scores were counted. One-way analysis of variance followed by Bonferroni correction. Results were representative of the three experiments performed. Error bars represent SD. (C) Expression of S100a9, Tnf alpha , Il1 beta , Il6, Il17a, Ifn gamma , Il12a, Il23a, Il4, & Il10 mRNA, as assessed by quantitative real-time PCR in normal control & IgG Ab, or anti-S100a9 Ab-treated colitis tissues. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/29326691), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Immunohistochemistry: S100A9 Antibody [NB110-89726] - Anti-S100a9 Ab ameliorates inflammatory response of dextran sulfate sodium (DSS)-induced colitis in mice. (A) 6 days after DSS treatment, representative H&E-stained colon sections were shown (upper panels: original magnification 40×, scale bar: 200 µm; lower panels: original magnification 100×, scale bar: 100 µm). (B) Colon inflammation, ulceration, & crypt damage were scored individually, & composite total score was scored. n = 5 per group. (C) Isolated lymphoid follicles (ILFs) area was measured at day 6. Representative TUNEL staining (D) & ethynyl-2′-deoxyuridine (EdU) staining (E) of normal mice & DSS-induced mice, which were treated with IgG Ab or anti-S100a9 Ab on day 6. The percent of positive cells was measured. At least six fields were counted per mouse. Scale bar, 100 µm. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/29326691), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Immunohistochemistry: S100A9 Antibody [NB110-89726] - Host CP (S100A8/A9) is elevated in H. pylori infected stomach tissue.A) s100a8/s100a9 transcript abundance in RNA extracted from C57BL/6 mice infected with H. pylori PMSS1 or SS1 for 1, 2, or 3 months relative to uninfected animals as determined by real-time RT-PCR analysis. Points indicate mean relative units of transcript abundance +/− SEM (levels of s100a8 in PMSS1-infected mice compared to uninfected mice; 1 mo p = 0.0511; 2 mo p = 0.0432; 3 mo p = 0.0127; levels of s100a8 in SS1-infected mice compared to uninfected mice at 2 mo p = 0.0623 Student's t test). (B) Inflammation scores of H. pylori infected mice at 1, 2, & 3 months post infection. (C) s100a8/s100a9 transcript abundance in RNA extracted from gastric biopsies derived from human patients, which were either H. pylori-positive or H. pylori-negative (s100a8 p = 0.15; s100a9 *p = 0.05). Bars indicate mean relative units of transcript abundance +/− SEM. Each experimental group represents≥5 individuals (mice or human samples). D) Gastric samples derived from H. pylori PMSS1-infected WT mice or SS1-infected WT mice at 2 months post-infection were analyzed via immunohistochemistry using a polyclonal antibody to S100A9 (scale bars are 50 microns). E) Real-time RT-PCR was performed on gastric tissue to quantify s100a8 & s100a9 transcript abundance from WT (C57BL/6 mice) & IL-17RA-/- mice infected with PMSS1. Data represent relative units of transcript abundance +/− SEM in WT mice & IL-17RA-/- mice, *p = 0.0169 & p = 0.0143, respectively. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/25330071), licensed under a CC0-1.0 license. Not internally tested by Novus Biologicals.

Immunohistochemistry: S100A9 Antibody [NB110-89726] - Anti-S100a9 Ab ameliorates inflammatory response of dextran sulfate sodium (DSS)-induced colitis in mice. (A) 6 days after DSS treatment, representative H&E-stained colon sections were shown (upper panels: original magnification 40×, scale bar: 200 µm; lower panels: original magnification 100×, scale bar: 100 µm). (B) Colon inflammation, ulceration, & crypt damage were scored individually, & composite total score was scored. n = 5 per group. (C) Isolated lymphoid follicles (ILFs) area was measured at day 6. Representative TUNEL staining (D) & ethynyl-2′-deoxyuridine (EdU) staining (E) of normal mice & DSS-induced mice, which were treated with IgG Ab or anti-S100a9 Ab on day 6. The percent of positive cells was measured. At least six fields were counted per mouse. Scale bar, 100 µm. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/29326691), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Immunohistochemistry: S100A9 Antibody [NB110-89726] - Anti-S100a9 Ab ameliorates inflammatory response of dextran sulfate sodium (DSS)-induced colitis in mice. (A) 6 days after DSS treatment, representative H&E-stained colon sections were shown (upper panels: original magnification 40×, scale bar: 200 µm; lower panels: original magnification 100×, scale bar: 100 µm). (B) Colon inflammation, ulceration, & crypt damage were scored individually, & composite total score was scored. n = 5 per group. (C) Isolated lymphoid follicles (ILFs) area was measured at day 6. Representative TUNEL staining (D) & ethynyl-2′-deoxyuridine (EdU) staining (E) of normal mice & DSS-induced mice, which were treated with IgG Ab or anti-S100a9 Ab on day 6. The percent of positive cells was measured. At least six fields were counted per mouse. Scale bar, 100 µm. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/29326691), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

• Reactivity: Hu, Mu, Rt
• Applications: WB, Simple Western, ICC/IF, IHC
• Clonality: Polyclonal
• Host: Rabbit
• Conjugate: Unconjugated
• Format: BSA Free

S100A9 Antibody - BSA Free Summary

• Immunogen: Full length human S100A9 protein [Swiss-Prot# P06702] expressed in E. coli.
• Isotype: IgG
• Clonality: Polyclonal
• Host: Rabbit
• Gene: S100A9
• Purity: Unpurified

Applications/Dilutions

• Dilutions:
  • Immunocytochemistry/ Immunofluorescence 1:50-1:200
  • Immunohistochemistry reported in scientific literature (PMID 25792748)
  • Immunohistochemistry-Paraffin reported in scientific literature (PMID 21653680)
  • Simple Western 1:100
  • Western Blot 1:1000
• Application Notes: In Western blot, a band is seen at approx. 16 kDa.
  
  In Simple Western only 10 - 15 uL of the recommended dilution is used per data point.
  See Simple Western Antibody Database for Simple Western validation: Tested in Human PBMC's lysate 0.5 mg/mL, separated by Size, antibody dilution of 1:100. Separated by Size-Wes, Sally Sue/Peggy Sue.
  The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
• Theoretical MW: 16 kDa.
  Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
• Control:

  S100A9 Overexpression Lysate

Packaging, Storage & Formulations

• Storage: Store at 4C short term. Aliquot and store at -20C long term. Avoid freeze-thaw cycles.
• Buffer: Whole antisera
• Preservative: 0.1% Sodium Azide
• Purity: Unpurified

Alternate Names for S100A9 Antibody - BSA Free

• CAGBMigration inhibitory factor-related protein 14
• Calgranulin B
• calgranulin-B
• Calprotectin L1H subunit
• CFAGMRP-14,60B8AG
• CGLB
• L1AG
• LIAG
• MAC387
• MIF
• MRP-14
• MRP14Leukocyte L1 complex heavy chain
• NIF
• P14
• protein S100-A9
• S100 calcium binding protein A9 (calgranulin B)
• S100 calcium binding protein A9
• S100 calcium-binding protein A9 (calgranulin B)
• S100 calcium-binding protein A9
• S100A9

Background

S100A9 (S100 calcium-binding protein A9) is a member of S-100 family (family named so as its members are 100% solubile in ammonium sulfate at normal pH) and it exist as a homodimer or as heterodimer/heterotetramer with S100A8. S100A9 is a calcium binding protein with several post-translation modifications as well as multiple ligands, and when bound to calcium, it binds to arachidonic acid, cytoskeletal elements (e.g. keratin intermediate filaments), RAGE (receptor for advanced glycation endproducts), TLR4, CD36, MMPs, fibronectin, and heparin sulfate glycosaminoglycans for serving diverse biological functions. Localization of S100A9 varies according to cell type/disease state, however, it predominantly localize to cytoplasm, from where it translocates to cytoskeleton/cell membrane upon elevation of intracellular calcium levels. During neutrophil activation or endothelial adhesion of monocytes, it gets secreted via a microtubule-mediated alternative pathway. S100A9 is expressed in normal cell types such as myeloid cells, but its expression levels are increased in conditions of inflammatory diseases (RA, SLE, cystic fibrosis, inflammatory bowel disease, Crohn's disease, Sjogren's syndrome, and progressive systemic sclerosis) as well as in several types of cancers including gastric, esophageal, colon, pancreatic, bladder, ovarian, thyroid, breast and skin cancers.

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Publications for S100A9 Antibody (NB110-89726)(26)

Publications using NB110-89726

• Yoshikawa T, Takeichi T, Hirabayashi T et al. IL-17 axis is a significant driver of skin inflammation in Card14 mutant pityriasis rubra pilaris model mice Research Square 2023-02-02 (IHC, Mouse)
• Li Z, Zhang X, Liu C Et al. Macrophage-Biomimetic Nanoparticles Ameliorate Ulcerative Colitis through Reducing Inflammatory Factors Expression Journal of innate immunity 2021-11-01 [PMID: 34724662] (IHC-P, Mouse)
• Bui TM, Butin-Israeli V, Wiesolek HL et al. Neutrophils Alter DNA Repair Landscape to Impact Survival and Shape Distinct Therapeutic Phenotypes of Colorectal Cancer Gastroenterology 2021-03-19 [PMID: 33753103] (Mouse)
• Kwak T, Wang F, Deng H et al. Distinct Populations of Immune-Suppressive Macrophages Differentiate from Monocytic Myeloid-Derived Suppressor Cells in Cancer Cell reports 2020-12-29 [PMID: 33378668]
• Mabuchi S, Komura N, Sasano T et Al. Pretreatment tumor-related leukocytosis misleads positron emission tomography-computed tomography during lymph node staging in gynecological malignancies Nat Commun 2020-03-13 [PMID: 32170086] (IF/IHC, Human)
• Kingsley MK, Bhat BV, Badhe BA et al. Narciclasine improves outcome in sepsis among neonatal rats via inhibition of calprotectin and alleviating inflammatory responses Sci Rep 2020-02-19 [PMID: 32076015] (IHC-P, IF/IHC, Rat)
• Duan X, Liu X, Liu N et al. Inhibition of keratinocyte necroptosis mediated by RIPK1/RIPK3/MLKL provides a protective effect against psoriatic inflammation Cell Death Dis 2020-02-19 [PMID: 32075957] (WB, Human, Mouse)
• Wang X, Liu X, Liu N, Chen H Prediction of crucial epigenetically associated, differentially expressed genes by integrated bioinformatics analysis and the identification of S100A9 as a novel biomarker in psoriasis Int. J. Mol. Med. 2019-10-31 [PMID: 31746348] (WB, Mouse)
• Zhang X, Wei L, et al. Suppression Colitis and Colitis-Associated Colon Cancer by Anti-S100a9 Antibody in Mice. Front Immunol 2018-01-13 [PMID: 29326691] (IF/IHC, Mouse)
• Lee TH, Chang HS, Bae DJ et al. Role of S100A9 in the development of neutrophilic inflammation in asthmatics and in a murine model Clin. Immunol. 2017-08-25 [PMID: 28847516] (WB, Mouse)
• Chernov AV, Dolkas J, Hoang K et al. Calcium-binding proteins S100A8 and S100A9 initiate the early inflammatory program in injured peripheral nerve. J. Biol. Chem. 2015-03-19 [PMID: 25792748] (IF/IHC, WB, Rat)
• Gaddy Ja, Radin Jn, Loh Jt et al. The Host Protein Calprotectin Modulates the Helicobacter pylori cag Type IV Secretion System via Zinc Sequestration. PLoS Pathog. 2014-10-01 [PMID: 25330071] (IHC-P, Mouse)
• Langle Y, Sandes E, Belgorosky D. La expresion de S100A9, vinculada con el oxidontrico, es un marcador de mal pronostico enpacientes con cancer de vejiga, siendo su inhibicionun posible blanco terapeutico. Rev. Arg. de Urol. 2014-03-01
• Luckett, T;Abudula, M;Ireland, L;Glenn, M;Bellomo, G;Stafferton, R;Halloran, C;Ghaneh, P;Jones, R;Schmid, MC;Mielgo, A; Mesothelin Secretion by Pancreatic Cancer Cells Co-opts Macrophages and Promotes Metastasis Cancer research 2024-02-15 [PMID: 38356443]
• Turchi R, Tortolici F, Benvenuto M et al. Low Sulfur Amino Acid, High Polyunsaturated Fatty Acid Diet Inhibits Breast Cancer Growth International Journal of Molecular Sciences 2022-12-23 (IHC-Fr, Mouse)
• Fong LY, Huebner K, Jing R et al. Zinc treatment reverses and anti-Zn-regulated miRs suppress esophageal carcinomas in vivo Proceedings of the National Academy of Sciences of the United States of America 2023-05-16 [PMID: 37155893]
• Manzanares LD, David J, Ren X et al. Atovaquone attenuates experimental colitis by reducing neutrophil infiltration of colonic mucosa Frontiers in Pharmacology 2022-10-14 [PMID: 36313299] (Immunohistochemistry-Paraffin, Mouse)
• Ancey PB, Contat C, Boivin G et al. GLUT1 Expression in Tumor-Associated Neutrophils Promotes Lung Cancer Growth and Resistance to Radiotherapy Cancer Research 2021-05-01 [PMID: 33753374] (Immunohistochemistry-Paraffin, Mouse)
• Tae-Rin Kwon, Sung-Eun Lee, Jong Hwan Kim, You Na Jang, Su-Young Kim, Seok Kyun Mun, Chan Woong Kim, Jungtae Na, Beom Joon Kim 310 nm UV-LEDs attenuate imiquimod-induced psoriasis-like skin lesions in C57BL/6 mice and inhibit IL-22-induced STAT3 expression in HaCaT cells. Photochemical & photobiological sciences : Official journal of the European Photochemistry Association and the European Society for Photobiology 2020-12-21 [PMID: 32584352]
• Langle YV, Balarino NP, Belgorosky D et Al. Effect of nitric oxide inhibition in Bacillus Calmette-Guerin bladder cancer treatment Nitric Oxide 2020-12-29 [PMID: 32147582]
• Fong Ly, Taccioli C, Palamarchuk A et Al. Abrogation of esophageal carcinoma development in miR-31 knockout rats Proc. Natl. Acad. Sci. U.S.A. 2020-03-17 [PMID: 32123074] (Immunohistochemistry-Paraffin, Mouse)
• Ikubo K, Yamanishi K, Doe N et al. Molecular analysis of the mouse brain exposed to chronic mild stress: The influence of hepatocyte nuclear factor 4a on physiological homeostasis. Mol Med Rep 2017-05-11 [PMID: 28498421]
• Zhang X, Ai F, Li X et al. Inflammation-induced S100A8 activates Id3 and promotes colorectal tumorigenesis. Int J Cancer 2015-12-15 [PMID: 26135667] (IHC-P, Mouse, Human)
• Sumi D, Shimizu Y, Himeno S. Involvement of Nrf2 activation in the upregulation of S100A9 by exposure to inorganic arsenite. Int J Mol Med. 2013-01-01 [PMID: 23165982]
• Pitteri SJ, Kelly-Spratt KS, Gurley KE et al. Tumor microenvironment-derived proteins dominate the plasma proteome response during breast cancer induction and progression. Cancer Res 2011-08-01 [PMID: 21653680] (IHC-P, Mouse)
• Bui TM Dissecting the Diverse Phenotypes and Pathological Impacts of Neutrophils in Colitis-to-CRC Progression Thesis 2022-01-01

FAQs for S100A9 Antibody (NB110-89726). (Showing 1 - 3 of 3 FAQs).

1. Have any of your S100A9 antibodies been tested for use in neutralization, or blocking assays, on human samples?
   • Unfortunately at this time we have not tested, or received customer feedback on our S100A9 antibodies for use in blocking or neutralizing assays. If you were planning on testing any of our S100A9 antibodies for neutralizing or blocking capabilities, we would recommend our Innovator’s Reward Program. Under the terms of this program we would be happy to provide a credit for a free vial in exchange for new data on this previously untested or reported application. Please submit this data in the form of an online review. Additional <a href="http://www.novusbio.com/support/innovators-reward.html" target="_self">Innovators Reward Program</a> information can be found using this link.
2. We would like to stain paraffin embedded human intestinal tissue for Calprotectin. One question will be which cells express the majority of Calprotectin - invading neutrophils vs epithelium for example. The antibody list you provide is quite extensive. Which antibody would you recommend for our purpose? Which tissue would you recommend as positive control.
   • Nine of our antibodies to Calprotectin have been validated for IHC-P with human tissue, and you can see all of these products. A number of our IHC images were generated using human spleen samples, and as such this may be a good choice of a positive control tissue. We do sell a human spleen slide product, which is suitable for IHC-P. Unfortunately I do not have an in-depth knowledge of Calprotectin, however the image shown for our antibody with catalogue number NBP1-02826 demonstrates clear staining of neutrophils. The following paper also suggests that the protein is abundant in neutrophils: PMID 11435495.
3. We would like to know detail information about immunocytochemistry and immunofluorescence. Could you provide protocol and other image for our reference?
   • For our ICC testing of this product, our lab tested in A431 cells. This image is visible on our datasheet here: Datasheet. The lab followed the following protocol: Protocol, and used the antibody at a 1:100 dilution.

Bioinformatics

• Gene Symbol: S100A9
• Entrez:
  • 6280(Human)
  • 20200(Mouse)
  • 94195(Rat)
• Uniprot:
  • P06702()